Christopher Carlos is a Nephrology physician affiliated with University of California, San Francisco. OpenAlex indexes 10 publications with 356 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 Parnassus Ave
Department Of Medicine
San Francisco, CA 941432204
Telephone
415-502-5300Registry record last updated 1 Oct 2019.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202511 payments
- Novartis Pharmaceuticals CorporationProgram year20246 payments
- Travere Therapeutics, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
67.9%Angiotensin receptor blocker (ARB)18.8%Losartan Potassium89%Olmesartan Medoxomil11%Part D<11 patientsCalcium channel blocker11.4%Amlodipine Besylate83%Nifedipine Er17%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
17.7%SGLT2 inhibitor12%Jardiance51%Farxiga49%Part D<11 patientsGLP-1 receptor agonist3%Ozempic100%Part D<11 patients+ 1 more class in this area
Other
7.7%Phosphate Binder5.5%Sevelamer Carbonate100%Part D<11 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia2.2%Lokelma100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2018 per NIH RePORTER. The latest:
- Dialysis Rx to Yield Optimal UltrafilTration (DRYOUT)
University of California, San Francisco
FY2018$39,361F32DK118829
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intensive Home Blood Pressure Lowering in Patients With Advanced CKD
American Journal of Kidney Diseases
2024 - Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
Journal for ImmunoTherapy of Cancer
2022 - Acute kidney injury in patients treated with immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”